Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
VIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPreclinical: NRM-823, a Breakthrough T-Cell Engager Targeting Advanced Prostate Cancer
/in Immunotherapy, Preclinical Research/by MaxRPT04402 Reactivating PP2A: A Different Approach in Advanced Prostate Cancer Therapy
/in Preclinical Research/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxResults from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer
/in Clinical Trial, Localized/by MaxPhase 3 Trial of BMS-986365
/in Clinical Trial, Metastatic, Phase 3/by MaxA New Hope for Aggressive Prostate Cancer: Evexomostat’s Potential
/in Preclinical Research/by MaxNXP800: A Promising New Drug for Hormone-Resistant Prostate Cancer
/in Preclinical Research/by Max